Given the pleiotropic effects of IFN-γ and the fact that its receptor is expressed by virtually all cell types, in retrospect, it is not surprising that its systemic administration failed to have therapeutic benefit in MS. This evidence concerns the gene IFNG and myeloid sarcoma.